Experimental Therapeutics - Ferdynand Kos

Ferdynand Kos, Ph.D.

  • Staff Scientist, Department of Experimental Therapeutics

Ferdynand Kos, Ph.D.

Research Focus :
  • Immunology, regulation of T cell responses, T cell memory
  • Cancer immunotherapy, T cell-targeted vaccines
  • Immune monitoring
  • 2013-2015, Senior Research Technologist, Mayo Clinic, Scottsdale, AZ
  • 2004-2013, Research Associate, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
  • 2003-2004, Research Scientist, La Jolla Institute for Allergy and Immunology, Division of Vaccine Discovery, San Diego, CA
  • 2001-2003, Senior Research Scientist, Beckman Coulter, Inc., Immunomics Operations, San Diego, CA
  • 1996-2001, Assistant Professor, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA
  • 1993-1996, Postdoctoral Research Fellow, Stanford University, Department of Pathology, Stanford, CA
  • 1992-1993, Postdoctoral Research Fellow, University of Pennsylvania, Department of Microbiology, Philadelphia, PA
  • 1982-1988, Research Assistant, Center of Oncology, Department of Pathology, Krakow, Poland
  • 1992, Australian National University, John Curtin School of Medical Research, Canberra, Australia, Ph.D., Immunology
  • 1981, Jagiellonian University, Cracow, Poland, M.Sc., Biology/Biophysics
  • Chaudhuri L., Srivastava R., Kos F., Shrikant P.A.: Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD8+ T cells. Cancer Immunology and Immunotherapy 65, 869-874, 2016.
  • Ellsworth S., Balmanoukian A., Kos F., Nirschl C.J., Nirschl T.R., Grossman S.A., Luznik L., Drake C.G.: Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology 3, e27357, 2014.
  • Chen S., Li Y., Depontieu F.R., McMiller T.L., English A.M., Shabanowitz J., Kos F., Sidney J., Sette A., Rosenberg S.A., Hunt D.F., Mariuzza A., Topalian S.L.: Structure-based design of altered MHC Class II-restricted peptide ligands with heterogeneous immunogenicity. Journal of Immunology 191, 5097-5106, 2013.
  • Kanakry C.G., Hess A.D., Gocke, C.D., Thoburn C., Kos F., Meyer C., Briel J., Luznik L., Smith B.D., Levitsky H., Karp J.E.: Early lymphocyte recovery following intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood 117, 608-617, 2011.
  • Trimble C.L., Clark R.A., Thoburn C., Hanson N.C., Tassello J., Frosina D., Kos F., Teague J., Jiang Y., Barat N.C., Jungbluth A.A.: Human papillomavirus 16-associated cervical intraepithelial neoplasia in human excludes CD8 T cells from dysplastic epithelium. Journal of Immunology 185, 7107-7114, 2010.
  • Trimble C.L., Peng S., Thoburn C., Kos F., Wu T.C.: Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunology and Immunotherapy 59, 799-803, 2010.
  • Trimble C.L., Peng S., Kos F., Gravitt P., Viscidi R., Sugar E., Pardoll D., Wu T.C.: A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clinical Cancer Research 15, 361-367, 2009.
  • Janetzki S. et al.: Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunology and Immunotherapy 57, 303-315, 2008.
  • Oseroff C., Kos F., Bui H.-H., Peters B., Pasquetto V., Glenn J., Palmore T., Sidney J., Tscharke D.C., Bennink J.R., Southwood S., Grey H.M., Yewdell J.W., Sette A.: HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proceedings of the National Academy of Sciences of the United States of America 102, 13980-13985, 2005.
  • Chang J., Kos F., Nugent C., Kuus-Reichel K.: MHC Tetramers: A Tool for Direct Ex Vivo Detection and Enumeration of Tumor-Specific Cytotoxic T Lymphocytes. In: Cancer Diagnostics: Current and Future Trends. Eds. R.M. Nakamura, W.W. Grody, J.T. Wu., and R.B. Nagle. Humana Press, pp. 185-198, 2004.
  • Kos F.J., Chin C.S.: Costimulation of T cell receptor-triggered IL-2 production by Jurkat T cells via fibroblast growth factor receptor 1 upon its engagement by CD56. Immunology and Cell Biology 80, 364-369, 2002.
  • Kos F.J., Cornell D.L., Lipke A.B., Graham L.J., Bear H.D.: Protective role of IL-2 during activation of T cells with bryostatin 1. International Journal of Immunopharmacology 22, 645-652, 2000.
  • Müllbacher A., Lobigs M., Kos F.J., Langman R.: Alloreactive cytotoxic T-cell function, peptide nonspecific. Scandinavian Journal of Immunology 49, 563-569, 1999.
  • Kos F.J.: Regulation of adaptive immunity by natural killer cells. Immunologic Research 17, 303-312, 1998.
  • Kos F.J., Bear H.D.: Involvement of protein kinase C-in CD28-triggered cytotoxicity mediated by a human leukaemic cell line YT. Immunology 94, 575-579, 1998.
  • Kos F.J., Engleman E.G.: Immune regulation: a critical link between NK cells and CTLs. Immunology Today 17, 174-176, 1996.
  • Kos F.J., Engleman E.G.: Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells. Cellular Immunology 173, 1-6, 1996.
  • Kos F.J., Engleman E.G.: Requirement for natural killer cells in the induction of cytotoxic T cells. Journal of Immunology, 155, 578-584, 1995.
  • Ikonomidis G., Paterson Y., Kos F.J., Portnoy D.A.: Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. Journal of Experimental Medicine 180, 2209-2218, 1994.
  • Kos F.J., Müllbacher A.: Transfer of CD8+ T cells into SCID mice and activation of memory virus-specific cytotoxic T cells. Scandinavian Journal of Immunology 37, 523-528, 1993.
  • Kos F.J., Müllbacher A.: IL-2-independent activity of IL-7 in the generation of secondary antigen-specific cytotoxic T cell responses in vitro. Journal of Immunology 150, 387-393, 1993.
  • Kos F.J., Müllbacher A.: Induction of primary anti-viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7. European Journal of Immunology 22, 3183-3185, 1992.
  • Kos F.J., Müllbacher A.: Specific epitope-induced conversion of CD8+ memory cells into effector cytotoxic T lymphocytes in vitro: presentation of peptide antigen by CD8+ T cells. European Journal of Immunology 22, 1595-1601, 1992.
Back To Top